Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1004
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Teprotumumab,Selumetinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 21985784
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Selumetinib | Sensitivity | true |
| Teprotumumab | Sensitivity | true |